Cargando…

Patient-reported outcome measures in drugs for neurological conditions approved by European Medicines Agency 2017–2022

BACKGROUND: Regulatory agencies have been responsive to public demand for inclusion of the patient experience in evaluating and approving therapies. Over the years, patient-reported outcome measures (PROMs) have become increasingly prevalent in clinical trial protocols; however, their influence on r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ciani, Oriana, Meregaglia, Michela, Battaglia, Mario Alberto, Brichetto, Gianpaolo, Conte, Antonella, Gasperini, Claudio, Sansone, Valeria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344960/ https://www.ncbi.nlm.nih.gov/pubmed/37145229 http://dx.doi.org/10.1007/s10072-023-06825-6

Ejemplares similares

Patient-Reported Outcome Measures in Oncology Drugs Approved by the European Medicines Agency, 2017-2021
por: Ciani, Oriana, et al.
Publicado: (2023)

The Assessment of Patient-Reported Outcomes for the Authorisation of Medicines in Europe: A Review of European Public Assessment Reports from 2017 to 2022
por: Meregaglia, Michela, et al.
Publicado: (2023)

EQ-5D-5L Population Norms for Italy
por: Meregaglia, Michela, et al.
Publicado: (2022)

The European Medicines Agency's approval of new medicines for type 2 diabetes
por: Blind, Eberhard, et al.
Publicado: (2018)

HEALTH TECHNOLOGY ASSESSMENT OF MEDICAL DEVICES: A SURVEY OF NON-EUROPEAN UNION AGENCIES
por: Ciani, Oriana, et al.
Publicado: (2015)

Il ruolo degli esiti riferiti dal paziente nelle decisioni di rimborso e innovatività dei farmaci in Italia
por: Malandrini, Francesco, et al.
Publicado: (2023)

Extension of the European Medicines Agency (EMA) approval of trifluridine/tipiracil for gastric cancer
por: Alsina, Maria, et al.
Publicado: (2019)

Biomarker and Companion Diagnostics—A Review of Medicinal Products Approved by the European Medicines Agency
por: Orellana García, Laura Patricia, et al.
Publicado: (2021)

Post‐Marketing Requirements for Cancer Drugs Approved by the European Medicines Agency, 2004–2014
por: Cherla, Avi, et al.
Publicado: (2022)

European Medicines Agency approval summary: Zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancer
por: Stanel, Stefan Cristian, et al.
Publicado: (2017)

Regulators' Advice Can Make a Difference: European Medicines Agency Approval of Zynteglo for Beta Thalassemia
por: Schuessler‐Lenz, Martina, et al.
Publicado: (2019)

The evidence base for psychotropic drugs approved by the European Medicines Agency: a meta-assessment of all European Public Assessment Reports
por: Erhel, Florian, et al.
Publicado: (2020)

Reply to Commentary by Cummings (2022): Surrogate endpoints extend beyond biomarkers
por: Manyara, Anthony Muchai, et al.
Publicado: (2022)

Availability and Affordability of Drugs With a Conditional Approval by the European Medicines Agency; Comparison of Korea With Other Countries and the Implications
por: Kwon, Hye-Young, et al.
Publicado: (2018)

Comparison of COVID-19 Vaccine Approvals at the US Food and Drug Administration, European Medicines Agency, and Health Canada
por: Lythgoe, Mark P., et al.
Publicado: (2021)

Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
por: Davis, Courtney, et al.
Publicado: (2017)

FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023)

A scoping review of core outcome sets and their ‘mapping’ onto real-world data using prostate cancer as a case study
por: Meregaglia, Michela, et al.
Publicado: (2020)

EHPnet: European Chemicals Agency
por: Dooley, Erin E.
Publicado: (2008)

Mesenchymal Stem Cell Therapies Approved by Regulatory Agencies around the World
por: Fernández-Garza, Luis E., et al.
Publicado: (2023)

FDA-Approved Small Molecules in 2022: Clinical Uses and Their Synthesis
por: Benedetto Tiz, Davide, et al.
Publicado: (2022)

Availability, accessibility and delivery to patients of the 28 orphan medicines approved by the European Medicine Agency for hereditary metabolic diseases in the MetabERN network
por: Heard, Jean-Michel, et al.
Publicado: (2020)

Financial regulations of the European Space Agency
por: European Space Agency. Paris. Administrative and Finance Committee
Publicado: (1999)

Data processing at the European Space Agency
por: Mazza, C
Publicado: (1982)

Validity of Surrogate Endpoints and Their Impact on Coverage Recommendations: A Retrospective Analysis across International Health Technology Assessment Agencies
por: Ciani, Oriana, et al.
Publicado: (2021)

Pharmacogenetic‐Pharmacokinetic Interactions in Drug Marketing Authorization Applications via the European Medicines Agency Between 2014 and 2017
por: Maliepaard, Marc, et al.
Publicado: (2020)

Real-world outcomes associated with new cancer medicines approved by the Food and Drug Administration and European Medicines Agency: A retrospective cohort study
por: Boyle, Jemma M., et al.
Publicado: (2021)

The role of health technology assessment bodies in shaping drug development
por: Ciani, Oriana, et al.
Publicado: (2014)

Use of real-world evidence in postmarketing medicines regulation in the European Union: a systematic assessment of European Medicines Agency referrals 2013–2017
por: Brown, Jeremy Philip, et al.
Publicado: (2019)

OxyContin was submitted and justifiably approved by the agency as a 12-hour dosage form
por: Fudin, Jeffrey, et al.
Publicado: (2016)

Assessment of Food and Drug Administration– and European Medicines Agency–Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
por: Arciero, Vanessa, et al.
Publicado: (2021)

41st symposium of the European Space Agency
por: Macchetto, F Duccio
Publicado: (2010)

Psychopharmacology at the era of EMEA (European Medicines Agency)
por: Pestana, Luis Camara, et al.
Publicado: (2010)

International Symposium on the History of the European Space Agency
por: Harris, R A
Publicado: (1999)

A bacteriophage journey at the European Medicines Agency
por: Debarbieux, Laurent, et al.
Publicado: (2015)

MEPs approve plans for European CDC
por: Rogers, Arthur
Publicado: (2004)

The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011–2018
por: Schuster Bruce, Catherine, et al.
Publicado: (2019)

Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis
por: Naci, Huseyin, et al.
Publicado: (2019)

New FDA approved antibacterial drugs: 2015-2017
por: Andrei, Stefan, et al.
Publicado: (2018)

Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study
por: Wallach, Joshua D., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_3jv1iejiclpb54b1vjete1gage